Business Wire

Cohere Acquires Reliant AI to Expand Sovereign Enterprise AI for the Global Biopharma and Healthcare Sectors

19.5.2026 15:00:00 CEST | Business Wire | Press Release

Share

Cohere, the world’s leading sovereign AI company, announced today the acquisition of Reliant AI, a leading biopharma AI company with operations in Montreal and Berlin. This acquisition brings Reliant AI’s world-class research team, proprietary biomedical datasets, and domain-optimized technology into Cohere’s enterprise-grade sovereign AI platform. This significantly expands Cohere’s footprint in the global healthcare and life sciences sectors–where security, data privacy, and regulatory compliance are paramount—and builds on Cohere’s existing partnerships across administrative, clinical, and revenue cycle workflows.

The acquisition strengthens Cohere’s position as global sovereign AI leader, building on its established presence in Canada and Germany and growing momentum across Europe. Together, Cohere and Reliant AI will equip healthcare and life sciences enterprises with a powerful combination of cutting-edge AI technology, secure deployment options for highly regulated environments, and deep domain expertise to improve processes and bring projects to market faster. This ensures enterprises and governments worldwide can deploy advanced models and systems with full control over their data, infrastructure, and compliance boundaries.

“We’re excited to welcome the Reliant AI team to Cohere as we deepen our work across healthcare and biopharma,” said Aidan Gomez, Co-founder and CEO, Cohere. “Healthcare represents one of the most consequential opportunities for AI and it demands secure, sovereign, and domain-specific systems. Together, we will accelerate progress in healthcare, building on our shared footprint across Canada and Germany to serve these critical sectors. We look forward to bringing North for Pharma to customers and partners as a cornerstone in our expanding portfolio of industry-specific AI products.”

Reliant AI’s flagship product is an intelligent research workbench used by global biopharma organizations to automate systemic literature reviews, competitive landscaping, and extraction of unstructured scientific and regulatory data. The platform also enables rapid identification of therapeutic precedents and modelling of market viability, dramatically accelerating decision-making and time to market.

Reliant was founded in 2023 by Karl Moritz Hermann, Richard Schlegel and Marc G. Bellemare (Canada CIFAR AI Chair, Mila).

"Joining Cohere represents a transformative opportunity to scale our biopharma AI solutions globally while maintaining the security and sovereignty that life sciences organizations require,” said Karl Moritz Hermann, CEO of Reliant AI. “Our combined expertise will accelerate drug discovery and research innovation for customers around the world.”

By integrating these capabilities, Cohere will accelerate the development of North for Pharma, an agentic AI system purpose-built to enhance productivity and efficiency for teams in the biopharma sector working across R&D, clinical development, and scientific analytics. North for Pharma extends Cohere’s growing suite of North offerings for regulated industries, including finance and telecoms. Reliant AI co‑founder and CEO Karl Moritz Hermann will join Cohere as VP of AI Verticalizations in Berlin, while fellow co‑founder Marc Bellemare will serve as VP of Modeling from Montreal.

The deal further unlocks new opportunities across the sector with specialized AI models and solutions tailored to pharmaceutical and biotechnology workflows–addressing challenges that general-purpose AI cannot. As part of the agreement, Cohere will assume Reliant AI’s customer relationships, including GSK, Medicus Pharma, and Kyowa Kirin, and will continue on advancing Reliant AI’s ongoing engagements with major pharmaceutical companies.

About Cohere

Cohere, founded 2019, is a security-first enterprise AI leader building foundation models and end-to-end products to solve business problems. We partner with organizations to deliver seamless integration, customization, and user-friendly solutions. Our all-in-one platform provides maximum security, privacy, and deployment flexibility across clouds, private environments, and on-premises. Headquartered globally in Toronto, San Francisco, Cohere operates additional offices in London, New York, Montreal, Paris, and Seoul, serving customers worldwide.

The company has raised ~$1.6BUSD from strategic tech investors (Nvidia, AMD Ventures, Salesforce Ventures, Oracle, Cisco), institutional investors (Radical Ventures, Inovia Capital, PSP Investments, HOOPP, BDC, Nexxus), and AI pioneers including Geoffrey Hinton, Fei-Fei Li, Pieter Abbeel, and Raquel Urtasun. For more information, visit cohere.com.

About Reliant AI

Reliant AI is the leading gen AI-powered data analytics platform for biopharma. Built by world-class NLP and reinforcement learning researchers with backgrounds at DeepMind, Google Brain, and EY Parthenon, Reliant AI simplifies the process of collecting, organizing, and analyzing complex data to deliver decision-critical insights for life sciences teams. Its flagship product, Reliant Tabular, helps analysts find scientific evidence for their decisions through automated systematic reviews, asset scans, and comprehensive analyses — cutting hours of data wrangling to seconds.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260519725513/en/

Contacts

Media Contacts
Cohere
Amanda Taggart
VP, Communications
amanda.taggart@cohere.com
+1 310 980 9587

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press Release

Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima

Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 16:25:00 CEST | Press Release

Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensuring your investment is delivering.” The rapid growth of the residential solar market created a growing population of “orphaned” solar sy

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press Release

A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press Release

Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press Release

Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye